[February 26, 2015]

Research and Markets: Pulmonary Fibrosis Therapeutics Pipeline Review 2015 - 56 Companies

Research and Markets (http://www.researchandmarkets.com/research/qs2vdz/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development - 30 of the 56 Companies Featured

• AdAlta Pty Ltd.
• Aeolus Pharmaceuticals, Inc.
• AnaptysBio, Inc.
• Biogen Idec Inc.
• BiOrion Technologies B.V.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Carolus Therapeutics, Inc.
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• FibroGen, Inc.
• Five Prime Therapeutics, Inc.
• Galectin Therapeutics, Inc.
• GenKyoTex S.A.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• IMMD Inc.
• ImmuneWorks, LLC
• IntelGenx Corp.
• LTT Bio-Pharma Co., Ltd.
• MedImmune, LLC
• Pacific Therapeutics Ltd.
• Pharmaxis Limited
• ProMetic Life Sciences Inc.
• Pulmatrix, Inc.
• RestorGenex Corporation
• Rhizen Pharmaceuticals SA
• Sanofi
• Therametrics holding AG

For more information visit http://www.researchandmarkets.com/research/qs2vdz/pulmonary

[ Back To TMCnet.com's Homepage ]